Id: CBI_1581 | Pages: 246 | Format : PDF | Published : | Author : Pawan Chasta | Category : Healthcare
Active B12 Test Market size is estimated to reach over USD 264.18 Million by 2031 from a value of USD 182.29 Million in 2023 and is projected to grow by USD 187.70 Million in 2024, growing at a CAGR of 4.7% from 2024 to 2031.
The Active B12 Test is a diagnostic tool that measures the biologically active form of vitamin B12, known as holotranscobalamin, in the bloodstream. This test enables early detection of vitamin B12 deficiencies, which can lead to serious health issues like neurological and hematological disorders if untreated. By focusing on the active portion of vitamin B12, it offers a more precise diagnosis than conventional total B12 tests, allowing healthcare providers to initiate timely intervention. Primary end-users include hospitals, diagnostic laboratories, and research institutions, which rely on accurate and early diagnosis for effective patient management. As healthcare providers focus more on preventive diagnostics, the market is expected to witness consistent growth driven by heightened health awareness and technological advancements.
The growing prevalence of vitamin B12 deficiency worldwide, particularly in aging populations, is a primary driver for the active B12 test market growth. Vitamin B12 deficiency is linked to a range of health issues, including neurological disorders, anemia, and cardiovascular problems, underscoring the need for accurate and early diagnosis. Unlike total B12 tests, which measure inactive B12 bound to haptocorrin, active B12 tests provide a more precise indication of the bioavailable form of the vitamin (holotranscobalamin), which is directly involved in cellular metabolism. This differentiation is especially important for diagnosing deficiencies in patients where conventional tests may yield ambiguous results. Healthcare providers are increasingly relying on active B12 tests to improve diagnostic accuracy and deliver targeted treatment for deficiencies, particularly in high-risk groups such as the elderly, individuals with gastrointestinal disorders, and vegetarians. The expanding awareness among clinicians about the clinical benefits of active B12 testing is propelling the demand for this specific diagnostic solution in both developed and emerging markets.
Despite its diagnostic advantages, the active B12 test market demand is restrained by the high cost of advanced testing equipment and the limited availability of specialized diagnostic facilities, particularly in low- and middle-income regions. Active B12 testing requires sophisticated immunoassay equipment, which can be costly for healthcare providers, especially smaller clinics and labs operating with limited budgets. Additionally, as active B12 tests are relatively recent compared to traditional B12 assays, not all diagnostic facilities have the infrastructure or trained personnel to conduct these tests. This limits the accessibility of active B12 testing in rural areas and emerging markets, where conventional diagnostic methods are more prevalent. Thus, market analysis shows that the high costs associated with upgrading diagnostic equipment and training healthcare personnel further restrict the widespread adoption of active B12 testing, impacting market penetration, especially in resource-constrained settings.
The integration of active B12 testing into routine health checkups presents a substantial active B12 test market opportunity, particularly as preventive healthcare becomes a greater priority globally. Early detection of B12 deficiency can prevent serious health complications, and active B12 testing provides a more accurate assessment, which is essential for timely intervention. Many healthcare systems and providers are recognizing the value of incorporating active B12 tests into regular screenings, especially for high-risk populations such as older adults, individuals with dietary restrictions, and those with conditions affecting nutrient absorption. Additionally, with the rise of at-home diagnostics and telemedicine, there is potential for the development of simplified, user-friendly active B12 testing kits that patients can use outside of clinical settings. This trend toward preventive healthcare, coupled with technological advancements in point-of-care testing, positions the active B12 test market for expansion. Companies focusing on making active B12 testing more accessible and cost-effective for routine use are well-positioned to capture a growing share of this market.
Based on product type, the market is segmented into reagents & kits, analyzers, and consumables.
The reagents & kits segment accounted for the largest revenue of the total active B12 test market share in 2023.
The analyzers segment is anticipated to register the fastest CAGR during the forecast period.
Based on test type, the market is segmented into ELISA (enzyme-linked immunosorbent assay), RIA (radioimmunoassay), chemiluminescence immunoassay (CLIA), and others.
The ELISA segment accounted for the largest revenue share of 40.28% in 2023.
The CLIA segment is anticipated to register the fastest CAGR during the forecast period.
Based on indication, the market is segmented into pernicious anemia, folate deficiency, vitamin B12 deficiency, neurological disorders, and others.
The vitamin B12 deficiency segment accounted for the largest revenue of the overall active B12 test market share in 2023.
The neurological disorders segment is anticipated to register the fastest CAGR during the forecast period.
Based on end-users, the Active B12 Test market is segmented into hospitals, diagnostic laboratories, research institutes, specialty clinics, and others.
The diagnostic laboratories segment accounted for the largest revenue share in 2023.
The hospital segment is anticipated to register the fastest CAGR during the forecast period.
The regions covered are North America, Europe, Asia Pacific, the Middle East and Africa, and Latin America.
Asia Pacific region was valued at USD 40.63 Million in 2023. Moreover, it is projected to reach over USD 65.75 Million by 2031. Out of this, China accounted for 32.1% of the total market share. Asia-Pacific is witnessing the fastest growth in the market, driven by increasing healthcare investments and improving diagnostic capabilities in countries like China, Japan, and India. The rising prevalence of vitamin B12 deficiencies and growing awareness among healthcare professionals contribute to market expansion. Government initiatives to improve healthcare infrastructure and access to diagnostics further support growth. However, challenges such as limited access to specialized care in rural areas and affordability issues may impede the uptake of advanced diagnostic tests.
North America holds a substantial share of the market, primarily due to a well-established healthcare infrastructure and high awareness levels. The United States, in particular, has a significant patient population and access to advanced diagnostic options, including enzyme immunoassays and ELISA assays. The presence of major diagnostic companies investing in research and development further propels market growth. However, the high cost of testing and potential side effects may pose challenges to market expansion.
Europe represents a significant portion of the global market, with countries like Germany, France, and the UK leading in terms of diagnosis and treatment. The region benefits from strong government support for rare disease management and a robust healthcare system. Ongoing clinical trials and research efforts are enhancing the adoption of novel diagnostic methods. However, stringent regulatory frameworks and high costs associated with advanced diagnostics could challenge rapid market growth.
The active B12 test market analysis shows that the Middle East & Africa region shows promising potential in the market, particularly in countries like Saudi Arabia, the UAE, and South Africa. Increasing healthcare investments and rising incidences of vitamin B12 deficiencies drive the demand for advanced diagnostic options. The expanding medical tourism sector, particularly in the UAE, where high-quality diagnostics are offered, further supports market growth. Nonetheless, limited local manufacturing capabilities and the high cost of diagnostics remain barriers to broader market penetration in this region.
Latin America is an emerging market, with Brazil and Mexico being the primary growth drivers. The rising prevalence of vitamin B12 deficiencies and increasing focus on improving healthcare infrastructure contribute to the market's expansion. Government initiatives aimed at enhancing access to advanced diagnostics, combined with the region's increasing awareness of vitamin B12 deficiencies, support market growth. However, economic constraints and unequal access to advanced healthcare technologies in some areas present challenges to market development in this region.
The active B12 test market is highly competitive with major players providing products to the national and international markets. Key players are adopting several strategies in research and development (R&D), product innovation, and end-user launches to hold a strong position in the global active B12 test market. Key players in the active B12 test industry include -
Product Launches:
Mergers and Acquisitions:
Report Attributes | Report Details |
Study Timeline | 2018-2031 |
Market Size in 2031 | USD 264.18 Million |
CAGR (2024-2031) | 4.7% |
By Product Type |
|
By Test Type |
|
By Indication |
|
By End User |
|
By Region |
|
Key Players |
|
North America | U.S. Canada Mexico |
Europe | U.K. Germany France Spain Italy Russia Benelux Rest of Europe |
APAC | China South Korea Japan India Australia ASEAN Rest of Asia-Pacific |
Middle East and Africa | GCC Turkey South Africa Rest of MEA |
LATAM | Brazil Argentina Chile Rest of LATAM |
Report Coverage |
|
In 2023, the active B12 test market was USD 182.29 million.
In 2031, the market size of active B12 test is expected to reach USD 264.18 Million.
The product type, test type, indication, and end-user are the segments covered in this report.
Axis-Shield Diagnostics (UK), Abbott Laboratories (USA), Siemens Healthineers (Germany), DiaSorin S.p.A. (Italy), Roche Diagnostics (Switzerland), LifeSpan BioSciences, Inc. (USA), Demeditec Diagnostics GmbH (Germany) are the major players in the active B12 test market.